Selinexor | List of Frontiers open access articles

Mini Review

Published on 22 Sep 2025

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy

in Hematologic Malignancies

Muhamed Baljevic
Gary Schiller
Tomer M. Mark
Dane R. Van Domelen
Cristina Gasparetto

Frontiers in Oncology

doi 10.3389/fonc.2025.1649493

2,416 views

Review

Published on 20 May 2025

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges

in Pharmacology of Anti-Cancer Drugs

Ziyu Qie
Li Ma
Jie Tan
Xiaochun Peng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1602911

4,192 views
2 citations

Original Research

Published on 01 Dec 2021

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

in Hematologic Malignancies

Jack G. Fisher
Christopher J. Walker
Amber DP. Doyle
Peter WM. Johnson
Francesco Forconi
Mark S. Cragg
Yosef Landesman
Salim. I. Khakoo
Matthew D. Blunt

Frontiers in Oncology

doi 10.3389/fonc.2021.785635

8,123 views
21 citations

Case Report

Published on 07 Feb 2024

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine

in Hematologic Malignancies

Lu Liu
Xiaofeng Song
Wenhao Dong
Zhao Li
Dongmei Guo

Frontiers in Oncology

doi 10.3389/fonc.2024.1353818

2,749 views
2 citations

Original Research

Published on 23 Sep 2025

XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma

in Neuro-Oncology and Neurosurgical Oncology

Josephine A. Mapunda
Yuta Suzuki
Danielle Burgenske
Paul A. Decker
Lin Zhang
Jeanette E. Eckel-Passow
Jann N. Sarkaria
Gaspar J. Kitange

Frontiers in Oncology

doi 10.3389/fonc.2025.1633580

2,283 views
1 citation

Brief Research Report

Published on 24 Nov 2022

Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro

in Inflammation Pharmacology

Szilvia Baron
Tami Rashal
Dmitry Vaisman
Ronit Elhasid
Rachel Shukrun

Frontiers in Pharmacology

doi 10.3389/fphar.2022.1030991

4,248 views
9 citations

Original Research

Published on 18 Aug 2022

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms

in Cancer Molecular Targets and Therapeutics

Christopher J. Walker
Hua Chang
Leah Henegar
Trinayan Kashyap
Sharon Shacham
Josh Sommer
Michael J. Wick
Joan Levy
Yosef Landesman

Frontiers in Oncology

doi 10.3389/fonc.2022.808021

5,019 views
8 citations

Original Research

Published on 04 Aug 2023

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

in Pharmacology of Anti-Cancer Drugs

Xiwen Tong
Jie Jin
Bin Xu
Shuai Su
Li Li
Mengyuan Li
Yizhou Peng
Xia Mao
Wei Huang
Donghua Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1217701

3,830 views
4 citations

Case Report

Published on 19 Dec 2024

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

in Hematologic Malignancies

Yunshuo Xiao
Kun Yang
Qiuying Huang
Changqing Wei
Manlv Wei
Zhili Geng
Hui Wu
Tianhong Zhou
Xialoin Yin
Yali Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1477697

2,576 views
2 citations

Original Research

Accepted on 20 Feb 2026

Selinexor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib by Regulating the BAX/Bcl-2/PUMA Apoptotic Pathway and the XPO1/p27 Cell Cycle Pathway

in Cancer Molecular Targets and Therapeutics

Shenghong Du
Ling Wang
Chen Chen
Yu Sun
Qian Liu
Jingfei Shi
Feng Zhang
Kai Wang
Cui Chao

Frontiers in Oncology

Original Research

Published on 07 May 2019

A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs

in Cardiovascular and Smooth Muscle Pharmacology

Zuheng Liu
Haiping Tian
Jinghai Hua
Wanqiang Cai
Yujia Bai
Qiong Zhan
Wenyan Lai
Qingchun Zeng
Hao Ren
Dingli Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2019.00465

5,903 views
9 citations

Original Research

Published on 27 Nov 2025

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration

in Cancer Immunity and Immunotherapy

Xiaohui Feng
Yuntian Ding
Yuling Huang
Hancheng Qin
Xiaobo Wang
Yunxin Zeng

Frontiers in Immunology

doi 10.3389/fimmu.2025.1710230

1,266 views

Review

Published on 26 Apr 2022

Selinexor and COVID-19: The Neglected Warden

in Inflammation Pharmacology

Gomaa Mostafa-Hedeab
Hayder M. Al-kuraishy
Ali I. Al-Gareeb
Nermeen N. Welson
Gaber El-Saber Batiha
Carlos Adam Conte-Junior

Frontiers in Pharmacology

doi 10.3389/fphar.2022.884228

5,918 views
29 citations

Case Report

Published on 08 Jul 2025

Isolated relapse of multiple myeloma in the central nervous system post autologous hematopoietic stem cell transplantation: a case report and literature review

in Hematologic Malignancies

Ying Zhou
Qian Shen
Jie Zhang
Li Zhu
Qi Jiang
Xiaobing Miao

Frontiers in Oncology

doi 10.3389/fonc.2025.1628297

2,683 views
1 citation

Review

Published on 10 May 2024

Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management

in Inflammation

Dan Li
Hong Fang
Rong Zhang
Qian Xie
Yang Yang
Lin Chen

Frontiers in Immunology

doi 10.3389/fimmu.2024.1398927

5,581 views
4 citations

Systematic Review

Published on 03 Dec 2021

Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials

in Drugs Outcomes Research and Policies

Yali Tao
Hui Zhou
Ting Niu

Frontiers in Pharmacology

doi 10.3389/fphar.2021.758992

7,284 views
9 citations

Articles

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

Case report: Safety and efficacy of synergistic treatment using selinexor and azacitidine in patients with atypical chronic myeloid leukemia with resistance to decitabine

XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma

Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro

Selinexor inhibits growth of patient derived chordomas in vivo as a single agent and in combination with abemaciclib through diverse mechanisms

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports

Selinexor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib by Regulating the BAX/Bcl-2/PUMA Apoptotic Pathway and the XPO1/p27 Cell Cycle Pathway

A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration

Selinexor and COVID-19: The Neglected Warden

Isolated relapse of multiple myeloma in the central nervous system post autologous hematopoietic stem cell transplantation: a case report and literature review

Beyond oncology: Selinexor’s journey into anti-inflammatory treatment and long-term management

Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials